Pure red cell aplasia: Response to therapy with anti‐thymocyte globulin

Abkowitz, Janis L.; Powell, Jerry S.; Nakamura, J; Kadin, Marshall E.; Adamson, John W.

doi:10.1002/ajh.2830230408

Cited by 41 publications

(11 citation statements)

References 25 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As for the etiology of bone marrow failure, patients with non-idiopathic AA and disorders other than AA responded to ATG. This result is in accordance with previous reports [12][13][14], although the number of such patients was too small to draw any conclusions.…”

Section: Discussionsupporting

confidence: 95%

The status of antithymocyte globulin therapy for adult patients in Japan: retrospective analysis of a nationwide survey

et al. 2007

View full text Add to dashboard Cite

We conducted a nationwide survey on antithymocyte globulin (ATG) therapy for adult patients in Japan. We mailed questionnaires to 454 hospitals with hematology divisions, of which 181 (40%) responded, and the records of 448 patients were collected. Patient characteristics, hematological responses, and adverse effects were evaluated in 421 patients with sufficient data. A total of 366 patients had idiopathic aplastic anemia (AA), 29 had other types of AA, and 25 had other diseases. The response rate (RR) at 6 months was 54% for all patients, and 53% for those with idiopathic AA. Ten patients (2%) died within 30 days, and 11 (3%) died between 31 and 100 days after ATG therapy. In 346 patients with moderate to very severe AA, who received their first ATG therapy, factors that influence the outcomes of ATG therapy were extracted. Among 11 pre-treatment and therapy-related variables, three were found to be correlated with a higher RR: shorter duration of AA, no history of specific therapy for AA, and the use of CsA. Most notably, the RR of patients treated within 3 months of diagnosis, those between 3 months and 2 years, and those later than 2 years were 68% (130/190), 48% (54/113), and 13% (5/38), respectively.

show abstract

Section: Discussionsupporting

confidence: 95%

The status of antithymocyte globulin therapy for adult patients in Japan: retrospective analysis of a nationwide survey

et al. 2007

View full text Add to dashboard Cite

show abstract

“…ATG has also been reported to be a useful modality in treating PRCA [2,9,20,22]. Although none of our idiopathic cases responded to ATG, one of our two T-LGLL cases achieved a partial response.…”

Section: Discussionmentioning

confidence: 91%

Pure red cell aplasia: Clinical features and treatment results in 16 cases

Kwong

Wong

Liang

et al. 1996

Annals of Hematology

View full text Add to dashboard Cite

Pure red cell aplasia (PRCA) is a rare hematological disease characterized by selective marrow erythroid aplasia. We report the clinical features and treatment results of 16 Chinese patients with PRCA. Nine (56%) cases were not associated with any underlying disorders and were considered idiopathic, while seven patients (44%) had associated diseases, three involving the thymus, two with T large granular lymphocyte leukemia (T-LGLL), and one each with Stevens-Johnson syndrome and acute hepatitis A. Conventional-dose corticosteroid therapy resulted in complete remission in three of 13 patients. Cyclosporin A was used in six patients. There were three complete and one partial remissions. High-dose methylprednisolone was ineffective in four patients who failed conventional-dose corticosteroids but achieved complete remission in one patient with thymoma who did not respond to thymectomy. Antithymocyte globulin was used in four patients, resulting in partial remission in only one patient with concomitant T-LGLL. Intravenous gamma globulin and danazol were ineffective in three patients. Thymectomy was performed in two patients, with one patient remitting. This is the largest series of PRCA reported in an oriental population. Our results indicate that treatment of PRCA may still be problematic and better therapeutic strategy will have to be defined.

show abstract

“…[61][62][63] Antithymocyte globulin has also had very limited use in DBA. 64 Metoclopramide has also shown to be effective in DBA. Abkowitz et al 65 described a 33% hematologic response rate in a small group of patients with DBA using metoclopramide, a dopamine antagonist that induces the release of prolactin from the pituitary gland.…”

Section: Alternative Therapiesmentioning

confidence: 99%